| Drug General Information |
| Drug ID |
D06FDR
|
| Drug Name |
Didanosine |
|
| Synonyms |
didanosine; 69655-05-6; DIDEOXYINOSINE; Videx; Videx EC; Inosine, 2',3'-dideoxy-; ddIno; Didanosina; Didanosinum; DDI; BMY-40900; UNII-K3GDH6OH08; K3GDH6OH08; Didanosinum [INN-Latin]; Didanosina [INN-Spanish]; CHEBI:490877; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; NSC 612049; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; NCGC00159514-02; NCGC00090691-03; DRG-0016; BMY 40900; DSSTox_CID_2927 |
| Drug Type |
Small molecular drug |
| Therapeutic Class |
Anti-HIV Agents |
| Company |
Bristol-Myers Squibb |
| Structure |
|
| Drug Resistance Mutations |
| Target Name |
HIV Nucleoside reverse transcriptase |
Target Info |
| Uniprot ID |
POL_HV1B1(600-1159) |
| Species |
Human immunodeficiency virus type 1 (HIV-1) |
| Reference Sequence |
PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPV
FAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL
DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVI
YQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWT
VQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAE
LELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGA
HTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTP
PLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTN [Human immunodefici
ency virus type 1 (HIV-1)]
|
| Targeted Disease |
HIV infection |
| Drug Resistance Mutations |
| Mutation info |
Missense: L74V |
[1], [2], [3] |
| Level of Resistance |
High-level resistance |
|
| Mutation info |
Missense: M184I |
[1], [2] |
|
| Mutation info |
Missense: M184V |
[1], [2] |
|
| Mutation info |
Missense: M41L |
[1], [2] |
|
| Mutation info |
Missense: Q151L |
[1], [2] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Missense: Q151M |
[1], [2] |
| Level of Resistance |
High-level resistance |
|
| Mutation info |
Missense: T210W |
[1], [2] |
|
| Mutation info |
Missense: T215F |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: T215Y |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: T69D |
[1], [2] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Missense: V75A |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: V75M |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: V75S |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: V75T |
[1], [2] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Missense: K65N |
[2], [3] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Missense: K65R |
[2], [3] |
| Level of Resistance |
High-level resistance |
|
| Mutation info |
Missense: K70E |
[2], [3] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: K70G |
[2], [3] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: K70N |
[2], [3] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: K70Q |
[2], [3] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: K70S |
[2], [3] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: K70T |
[2], [3] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: L74I |
[4] |
| Mutation Frequency |
3-20% of the samples |
|
| Target Name |
HIV Non-Nucleoside reverse transcriptase |
Target Info |
| Uniprot ID |
POL_HV1B1(600-1159) |
| Species |
Human immunodeficiency virus type 1 (HIV-1) |
| Reference Sequence |
PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPV
FAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL
DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVI
YQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWT
VQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAE
LELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGA
HTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTP
PLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNKGRQKVVPLTNTTNQKTELQ
AIYLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLAWVPAHK
GIGGNEQVDKLVSAGIRKIL [Human immunodeficiency virus type 1 (H
IV-1)]
|
| Targeted Disease |
HIV infection |
| Drug Resistance Mutations |
| Mutation info |
Deletion: D67 |
[1], [2] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Deletion: K70 |
[1], [2] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Deletion: S68 |
[1], [2] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Insertion: T69 |
[1], [2] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Deletion: T69 |
[1], [2] |
| Level of Resistance |
Intermediate resistance |
|
| References |
| REF 1 |
Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther. 2004 Oct;9(5):695-702.
|
| REF 2 |
The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology. 2012;55(2):98-101.
|
| REF 3 |
Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1. Clin Invest Med. 1994 Jun;17(3):226-43.
|
| REF 4 |
Mechanisms of anti-retroviral drug resistance: implications for novel drug discovery and development. Infect Disord Drug Targets. 2013 Oct;13(5):330-6.
|
